Catal­ent inks $133M deal to buy Ju­niper Phar­ma­ceu­ti­cals, adding UK de­vel­op­ment ser­vices

The bio­phar­ma con­tract de­vel­op­er and man­u­fac­tur­er Catal­ent $CTLT has swooped in to buy out Ju­niper Phar­ma­ceu­ti­cals $JNP for $133 mil­lion, adding their ser­vices with an eye to amp­ing up its ear­ly drug de­vel­op­ment of­fer­ings in the UK.

The buy­out — at $11.50 a share — brings 150 staffers and their Ju­niper Phar­ma Ser­vices di­vi­sion in Not­ting­ham. Catal­ent is look­ing to add their ex­per­tise on for­mu­la­tion de­vel­op­ment, bioavail­abil­i­ty so­lu­tions and clin­i­cal-scale oral dose man­u­fac­tur­ing to the com­pa­ny’s glob­al op­er­a­tions. The com­pa­ny al­so man­ages the Crinone (prog­es­terone gel) fran­chise.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER